Neurogene Future Growth
Future criteria checks 2/6
Neurogene's earnings are forecast to decline at 29.9% per annum while its annual revenue is expected to grow at 83.3% per year. EPS is expected to decline by 22.5% per annum.
Key information
-29.9%
Earnings growth rate
-22.5%
EPS growth rate
| Biotechs earnings growth | 28.5% |
| Revenue growth rate | 83.3% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 25 Nov 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -107 | -101 | -100 | 4 |
| 12/31/2025 | N/A | -88 | -96 | -88 | 6 |
| 12/31/2024 | 1 | -77 | -86 | -58 | 6 |
| 9/30/2024 | 1 | -3 | -71 | -70 | N/A |
| 6/30/2024 | 1 | 2 | -67 | -66 | N/A |
| 3/31/2024 | N/A | 9 | -60 | -60 | N/A |
| 12/31/2023 | N/A | 14 | -52 | -51 | N/A |
| 9/30/2023 | N/A | -51 | -45 | -45 | N/A |
| 6/30/2023 | N/A | -49 | -44 | -44 | N/A |
| 3/31/2023 | N/A | -52 | -52 | -50 | N/A |
| 12/31/2022 | N/A | -55 | -55 | -53 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NGNE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NGNE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NGNE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NGNE's revenue (83.3% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: NGNE's revenue (83.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NGNE's Return on Equity is forecast to be high in 3 years time